口服缬更昔洛韦对巨细胞病毒单侧高血压性前葡萄膜炎的长期疗效

IF 2.6 4区医学 Q2 OPHTHALMOLOGY Ocular Immunology and Inflammation Pub Date : 2025-01-01 Epub Date: 2024-05-22 DOI:10.1080/09273948.2024.2356057

Abdulsalam M Dheyab, Abdulrahman F Albloushi, Asma Al-Zuabi, Sulaiman M AlTariqi, Mohannad F Tobaigy, Abdullah Alfawaz, Ahmed Abu El-Asrar

{"title":"口服缬更昔洛韦对巨细胞病毒单侧高血压性前葡萄膜炎的长期疗效","authors":"Abdulsalam M Dheyab, Abdulrahman F Albloushi, Asma Al-Zuabi, Sulaiman M AlTariqi, Mohannad F Tobaigy, Abdullah Alfawaz, Ahmed Abu El-Asrar","doi":"10.1080/09273948.2024.2356057","DOIUrl":null,"url":null,"abstract":"Purpose: To describe long-term efficacy and safety of oral valganciclovir in the treatment of presumed cytomegalovirus (CMV) unilateral hypertensive anterior uveitis.Methods: Retrospective review of 40 patients (40 eyes).Results: All patients presented with high intraocular pressure (mean 39.35 ± 7.58 mmHg), associated with signs of mild anterior uveitis. Oral valganciclovir resulted in control of the intraocular pressures and inflammation in 35 eyes. At the dose of ≥450 mg twice daily, no relapses were documented. The follow-up period ranged from 12 to 108 months (24.45 ± 14.56). At the final follow-up, the intraocular pressure was reduced to 14.92 ± 2.43 mmHg (<0.001). Drug-related complications in the form of leukopenia and azoospermia were reported in one patient.Conclusions: Oral valganciclovir effectively and safely controls intraocular pressure and inflammation in presumed CMV anterior uveitis. A long-term treatment course seems necessary.","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"72-79"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term Efficacy of Oral Valganciclovir in Presumed Cytomegalovirus Unilateral Hypertensive Anterior Uveitis.\",\"authors\":\"Abdulsalam M Dheyab, Abdulrahman F Albloushi, Asma Al-Zuabi, Sulaiman M AlTariqi, Mohannad F Tobaigy, Abdullah Alfawaz, Ahmed Abu El-Asrar\",\"doi\":\"10.1080/09273948.2024.2356057\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To describe long-term efficacy and safety of oral valganciclovir in the treatment of presumed cytomegalovirus (CMV) unilateral hypertensive anterior uveitis.Methods: Retrospective review of 40 patients (40 eyes).Results: All patients presented with high intraocular pressure (mean 39.35 ± 7.58 mmHg), associated with signs of mild anterior uveitis. Oral valganciclovir resulted in control of the intraocular pressures and inflammation in 35 eyes. At the dose of ≥450 mg twice daily, no relapses were documented. The follow-up period ranged from 12 to 108 months (24.45 ± 14.56). At the final follow-up, the intraocular pressure was reduced to 14.92 ± 2.43 mmHg (<0.001). Drug-related complications in the form of leukopenia and azoospermia were reported in one patient.Conclusions: Oral valganciclovir effectively and safely controls intraocular pressure and inflammation in presumed CMV anterior uveitis. A long-term treatment course seems necessary.\",\"PeriodicalId\":19406,\"journal\":{\"name\":\"Ocular Immunology and Inflammation\",\"volume\":\" \",\"pages\":\"72-79\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ocular Immunology and Inflammation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09273948.2024.2356057\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09273948.2024.2356057","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：描述口服缬更昔洛韦治疗推测的巨细胞病毒（CMV）单侧高眼压前葡萄膜炎的长期疗效和安全性：方法：对40例患者（40只眼）进行回顾性研究：结果：所有患者均出现高眼压（平均 39.35 ± 7.58 mmHg），并伴有轻度前葡萄膜炎的症状。口服缬更昔洛韦可控制 35 只眼睛的眼压和炎症。在剂量≥450毫克、每天两次的情况下，没有复发的记录。随访时间从 12 个月到 108 个月不等（24.45 ± 14.56）。在最后的随访中，眼压降至 14.92 ± 2.43 mmHg（结论：口服缬更昔洛韦可降低眼压，但不能降低眼压：口服缬更昔洛韦可有效、安全地控制假定巨细胞病毒前葡萄膜炎患者的眼压和炎症。看来有必要进行长期治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Long-term Efficacy of Oral Valganciclovir in Presumed Cytomegalovirus Unilateral Hypertensive Anterior Uveitis.

Purpose: To describe long-term efficacy and safety of oral valganciclovir in the treatment of presumed cytomegalovirus (CMV) unilateral hypertensive anterior uveitis.

Methods: Retrospective review of 40 patients (40 eyes).

Results: All patients presented with high intraocular pressure (mean 39.35 ± 7.58 mmHg), associated with signs of mild anterior uveitis. Oral valganciclovir resulted in control of the intraocular pressures and inflammation in 35 eyes. At the dose of ≥450 mg twice daily, no relapses were documented. The follow-up period ranged from 12 to 108 months (24.45 ± 14.56). At the final follow-up, the intraocular pressure was reduced to 14.92 ± 2.43 mmHg (<0.001). Drug-related complications in the form of leukopenia and azoospermia were reported in one patient.

Conclusions: Oral valganciclovir effectively and safely controls intraocular pressure and inflammation in presumed CMV anterior uveitis. A long-term treatment course seems necessary.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ocular Immunology and Inflammation 医学-眼科学

CiteScore

6.20

自引率

15.20%

发文量

285

审稿时长

6-12 weeks

期刊介绍： Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.